Published in J Antimicrob Chemother on January 01, 1985
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother (1991) 1.52
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Clinical significance of antibiotic tissue penetration. Clin Pharmacokinet (1989) 1.48
Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity. Antimicrob Agents Chemother (1990) 1.35
Clarithromycin transport by gingival fibroblasts and epithelial cells. J Dent Res (2008) 0.90
Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Antimicrob Agents Chemother (1994) 0.84
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother (1994) 3.73
Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet (1979) 2.71
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet (1995) 2.66
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med (1989) 2.56
Role for dual individualization with cefmenoxime. Am J Med (1984) 2.29
Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother (1995) 2.29
Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci (1984) 2.20
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother (1998) 2.19
Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther (1989) 2.08
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother (1993) 1.88
In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother (1990) 1.83
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother (1989) 1.74
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis (1998) 1.71
Inhibition of enoxacin absorption by antacids or ranitidine. Antimicrob Agents Chemother (1989) 1.59
Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther (1978) 1.59
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci (1979) 1.56
Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health Syst Pharm (1996) 1.53
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother (1991) 1.52
Liquid-chromatographic determination of ciprofloxacin in serum and urine. Clin Chem (1985) 1.52
Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother (1978) 1.51
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Gentamicin tissue accumulation and nephrotoxic reactions. JAMA (1978) 1.49
Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther (1977) 1.48
Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest (1995) 1.47
Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli. Antimicrob Agents Chemother (1988) 1.44
Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis (1992) 1.43
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents (2000) 1.43
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother (1997) 1.42
Alteration of theophylline clearance and half-life by cimetidine in normal volunteers. Ann Intern Med (1981) 1.41
Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm (1999) 1.41
Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med (1991) 1.40
Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J Antimicrob Chemother (1987) 1.33
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother (1994) 1.30
The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol (1988) 1.28
Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother (1981) 1.27
Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. Ann Pharmacother (1992) 1.25
Methicillin distribution in serum and extravascular fluid and its relevance to normal and damaged heart valves. Antimicrob Agents Chemother (1981) 1.22
Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother (1979) 1.21
Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med (1991) 1.19
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.19
Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions. Antimicrob Agents Chemother (1980) 1.19
Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. J Antimicrob Chemother (1984) 1.15
Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection (2004) 1.13
Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. J Pediatr (1980) 1.13
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm (2000) 1.12
Cortical input to the basal forebrain. Neuroscience (1997) 1.11
The neuronal organization of the supracapsular part of the stria terminalis in the rat: the dorsal component of the extended amygdala. Neuroscience (1998) 1.10
Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides. Kidney Int (1980) 1.08
Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects. Antimicrob Agents Chemother (1987) 1.08
Rate of methicillin penetration into normal heart valve and experimental endocarditis lesions. Antimicrob Agents Chemother (1982) 1.08
Intravenous theophylline therapy: nomogram guidelines. Ann Intern Med (1977) 1.07
Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther (1991) 1.07
Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet (1986) 1.07
High-pressure liquid chromatography analysis and single-dose disposition of tobramycin in human volunteers. Antimicrob Agents Chemother (1980) 1.07
Allopurinol sensitivity: report of two cases. Am J Hosp Pharm (1979) 1.06
The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. Antimicrob Agents Chemother (1993) 1.06
Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation. J Clin Pharm Ther (2002) 1.06
A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann Surg (1983) 1.06
Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J Med (1978) 1.05
Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother (1994) 1.05
Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimicrob Agents Chemother (1989) 1.04
Numerous length polymorphisms at short tandem repeats in human cytomegalovirus. J Virol (1999) 1.03
The pharmacokinetics and metabolism of cimetidine in neonates. Dev Pharmacol Ther (1984) 1.03
Next generation tools for high-throughput promoter and expression analysis employing single-copy knock-ins at the Hprt1 locus. Genomics (2008) 1.03
Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy (2000) 1.02
C-reactive protein as an indicator of infection relapse in patients with abdominal sepsis. Arch Surg (1984) 1.02
Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet (1999) 1.02
Pharmacodynamic modeling of bacterial kinetics: beta-lactam antibiotics against Escherichia coli. J Pharm Sci (1994) 1.02
Design and evaluation of consensus PCR assays for henipaviruses. J Virol Methods (2009) 1.02
Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood (1990) 1.01
Degradation kinetics of imipenem in normal saline and in human serum. Antimicrob Agents Chemother (1986) 1.01
Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology (2000) 0.99
Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother (1991) 0.99
False-positive "hemoccult" reaction with cimetidine. N Engl J Med (1980) 0.98
Mental confusion in a patient treated with metronidazole--a concentration-related effect? Pharmacotherapy (1983) 0.98
Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol (1998) 0.97
Comparative tissue accumulation of gentamicin and tobramycin in patients. J Antimicrob Chemother (1978) 0.96
Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers. Antimicrob Agents Chemother (1987) 0.96
Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens. Drug Intell Clin Pharm (1987) 0.96
Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin Pharmacokinet (2001) 0.96
Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol (2003) 0.96
Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother (1982) 0.95
Liquid-chromatographic determination of cimetidine, its known metabolites, and creatinine in serum and urine. Clin Chem (1981) 0.95
Effect of lomefloxacin on theophylline pharmacokinetics. Antimicrob Agents Chemother (1989) 0.94
Principles of antibiotic tissue penetration and guidelines for pharmacokinetic analysis. Med Clin North Am (1982) 0.94
Gentamicin persistence in the body. Lancet (1977) 0.94
The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. J Antimicrob Chemother (1988) 0.94
Therapeutic monitoring of aminoglycoside antibiotics: an approach. Ther Drug Monit (1980) 0.93
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Am J Med (1987) 0.93
Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother (1984) 0.92
Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP (1991) 0.92
Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother (1989) 0.92